Treating anemia of chronic kidney disease in the primary care setting: cardiovascular outcomes and management recommendations

Anemia is an underrecognized but characteristic feature of chronic kidney disease (CKD), associated with significant cardiovascular morbidity, hospitalization, and mortality. Since their inception nearly two decades ago, erythropoiesis-stimulating agents (ESAs) have revolutionized the care of patients with renal anemia, and their use has been associated with improved quality of life and reduced hospitalizations, inpatient costs, and mortality. Hemoglobin targets ≥13 g/dL have been linked with adverse events in recent randomized trials, raising concerns over the proper hemoglobin range for ESA treatment. This review appraises observational and randomized studies of the outcomes of erythropoietic treatment and offers recommendations for managing renal anemia in the primary care setting.

• Publication year

  2007

• Venue

  Osteopathic Medicine and Primary Care

• Publication date

  2007-10-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/1750-4732-1-14PMID 17910755PMCID 2147011
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target.

  2007cited by this paper
• KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target.

  2007cited by this paper
• An ongoing study of anemia correction in chronic kidney disease.

  2007cited by this paper
• Anemia Management in Chronic Heart Failure: Lessons Learnt from Chronic Kidney Disease

  2006influential reference
• Normalization of hemoglobin level in patients with chronic kidney disease and anemia.

  2006influential reference
• Primary care physicians' knowledge and practice patterns in the treatment of chronic kidney disease: an Upstate New York Practice-based Research Network (UNYNET) study.

  2006influential reference
• Anemia and cardiovascular risk: the lesson of the CREATE Trial.

  2006cited by this paper
• Care of elderly patients with chronic kidney disease

  2006cited by this paper
• Association of anemia with outcomes in men with moderate and severe chronic kidney disease.

  2006cited by this paper
• Anemia in chronic kidney disease: causes, diagnosis, treatment.

  2006influential reference
• III. Clinical practice recommendations for anemia in chronic kidney disease in children.

  2006cited by this paper
• Identification and referral of patients with progressive CKD: a national study.

  2006cited by this paper
• Hemoglobin Level, Chronic Kidney Disease, and the Risks of Death and Hospitalization in Adults With Chronic Heart Failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study

  2006cited by this paper
• Effect of early correction of anemia on the progression of CKD.

  2006cited by this paper
• Anaemia in diabetes: is there a rationale to TREAT?

  2006cited by this paper
• Chronic Kidney Disease: A Public Health Problem That Needs a Public Health Action Plan

  2006cited by this paper
• KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.

  2006cited by this paper
• The chronic kidney disease epidemic: stepping back and looking forward.

  2006cited by this paper
• KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.

  2006cited by this paper
• Anemia as a predictor of cardiovascular events in patients with elevated serum creatinine.

  2006cited by this paper
• Correction of anemia with epoetin alfa in chronic kidney disease.

  2006influential reference
• Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL.

  2005cited by this paper
• Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease

  2005cited by this paper
• Projecting the number of patients with end-stage renal disease in the United States to the year 2015.

  2005cited by this paper
• Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study.

  2005cited by this paper
• Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD.

  2005cited by this paper
• Anemia management and chronic renal failure progression.

  2005cited by this paper
• Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients.

  2005cited by this paper
• Caring for Patients with Chronic Kidney Disease: A Joint Opinion of the Ambulatory Care and the Nephrology Practice and Research Networks of the American College of Clinical Pharmacy

  2005influential reference
• Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients.

  2005cited by this paper
• Piecing together the evidence on anemia: the link between chronic kidney disease and cardiovascular disease.

  2005cited by this paper
• Piecing together the evidence on anemia: the link between chronic kidney disease and cardiovascular disease.

  2005influential reference
• Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial.

  2004influential reference
• Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy.

  2004cited by this paper
• Effects of Treatment with Epoetin Beta on Outcomes in Patients with Anaemia and Chronic Heart Failure

  2004cited by this paper
• Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population.

  2004cited by this paper
• Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial.

  2004cited by this paper
• The prevalence of anemia in patients with chronic kidney disease

  2004influential reference
• The Nephrologist as a Primary Care Provider for the Hemodialysis Patient

  2004cited by this paper
• The Incidence of End-Stage Renal Disease Is Increasing Faster than the Prevalence of Chronic Renal Insufficiency

  2004cited by this paper
• Clinical practice guidelines for chronic kidney disease in adults: Part I. Definition, disease stages, evaluation, treatment, and risk factors.

  2004cited by this paper
• The consequences and costs of chronic kidney disease before ESRD.

  2004cited by this paper
• Anemia as a risk factor and therapeutic target in heart failure.

  2004cited by this paper
• Anaemia as a risk factor for the progression of chronic kidney disease

  2003cited by this paper
• Chronic kidney disease: issues and establishing programs and clinics for improved patient outcomes.

  2003cited by this paper
• Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study.

  2003cited by this paper
• Effect of Erythropoietin on Exercise Capacity in Patients With Moderate to Severe Chronic Heart Failure

  2003cited by this paper
• Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial.

  2003cited by this paper
• Chronic kidney disease and cardiovascular disease in the Medicare population.

  2003cited by this paper
• The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron.

  2003influential reference
• Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey.

  2003cited by this paper
• Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994).

  2002cited by this paper
• Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey.

  2002cited by this paper
• clinical practice guidelines for chronic kidney disease : evaluation, classification, and stratification

  2002cited by this paper
• Health care utilization among patients with chronic kidney disease.

  2002cited by this paper
• Iron status and hemoglobin level in chronic renal insufficiency.

  2002cited by this paper
• Nephrologist care and mortality in patients with chronic renal insufficiency.

  2002influential reference
• K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

  2002cited by this paper
• Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients.

  2001cited by this paper
• The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study.

  2001cited by this paper
• Why is erythropoietin made in the kidney? The kidney functions as a critmeter.

  2001influential reference
• Use of erythropoietin before the initiation of dialysis and its impact on mortality.

  2001cited by this paper
• THE EFFECTS OF NORMAL AS COMPARED WITH LOW HEMATOCRIT VALUES IN PATIENTS WITH CARDIAC DISEASE WHO ARE RECEIVING HEMODIALYSIS AND EPOETIN

  2000cited by this paper
• The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations.

  2000cited by this paper
• Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology.

  2000cited by this paper
• Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin.

  1999influential reference
• Does early anemia correction prevent complications of chronic renal failure?

  1999cited by this paper
• Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center.

  1999influential reference
• The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.

  1998cited by this paper
• Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients.

  1997cited by this paper
• Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention.

  1996cited by this paper
• Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients.

  1995cited by this paper
• Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients.

  1994cited by this paper
• Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients.

  1992cited by this paper
• Epoetin and cognitive function.

  1992cited by this paper
• Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial.

  1989cited by this paper
• Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial.

  1989cited by this paper
• Erythropoietin in polycystic kidneys.

  1989cited by this paper
• Erythropoietin and anemia in chronic renal failure.

  1987cited by this paper
• A double‐blind, placebo‐controlled trial

  1986cited by this paper

• Efficacy and safety of Vadadustat in the treatment of anemia associated with chronic kidney disease: insights from clinical trials

  2024cites this paper
• The efficacy and safety of molidustat for anemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A systematic review and meta-analysis

  2024cites this paper
• Retrospective Analysis of Factors Influencing the Hemoglobin Level-increasing Effect of Sodium-glucose Co-transporter-2 Inhibitors

  2024influential citation
• Quantitative systems pharmacology model of erythropoiesis to simulate therapies targeting anemia due to chronic kidney disease

  2023cites this paper
• Framework of Guidelines for Management of CKD in Asia

  2023cites this paper
• Hematological Abnormalities and Comorbidities Are Associated With the Severity of Kidney Disease: A Hospital-Based Cross-Sectional Study in Bangladesh

  2022cites this paper
• Efficacy of N-SORB, a proprietary KD120 MEC metabolically activated enzyme formulation in digestion

  2022cites this paper
• Anemia in CKD in Primary Care: Executive Summary.

  2022cites this paper
• Improving Detection and Management of Anemia in CKD.

  2022influential citation
• Anaemia in chronic kidney disease

  2021cites this paper
• Anaemia in chronic kidney disease - a review

  2020cites this paper
• Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients.

  2020cites this paper
• A prospective observational study on the effect of Erythropoiesis stimulating agents in chronic disease Anemia patients

  2020cites this paper
• The association of interleukin-6 (−174 G/C) polymorphism with risk of chronic kidney disease and erythropoietin hyporesponsiveness

  2020cites this paper
• Safety and Efficacy of N-SORB®, a Proprietary KD120 MEC Metabolically Activated Enzyme Formulation: A Randomized, Double-Blind, Placebo-Controlled Study

  2019cites this paper
• Outpatient management of the anemic patient: is it a possible challenge?

  2019cites this paper
• Trends in the treatment of chronic kidney disease-associated anaemia in a cohort of haemodialysis patients: the Irish experience

  2019cites this paper
• Prevalence Of Anemia And Its Associated Factors Among Chronic Kidney Disease Patients At University Of Gondar Hospital, Northwest Ethiopia: A Hospital-Based Cross Sectional Study

  2019cites this paper
• Association of Pre-End-Stage Renal Disease Hemoglobin with Early Dialysis Outcomes

  2018cites this paper
• Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents

  2018cites this paper
• Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?

  2017cites this paper
• Assessment of Patient Perceptions about Use of Wepox Pen^TM (Recombinant Erythropoietin Delivery Device with 30,000 IU Cartridge) in the Management of Anemia in Chronic Kidney Disease Patients

  2017cites this paper
• Study of Management of anemia in Chronic Kidney Disease Patients

  2016cites this paper
• Iron Therapy Challenges for the Treatment of Nondialysis CKD Patients.

  2016cites this paper
• Anaemia in chronic kidney disease

  2016cites this paper
• Chronic kidney disease:comparing trends in primary and secondary care

  2016cites this paper
• Anemia in Chronic Kidney Disease (Ckd) Patients

  2015cites this paper
• Data Mining Approach in Prediction of Erythropoietin Dosage in Hemodialysis Patients

  2015cites this paper
• Haemoglobin levels in the chronic dialysis population in the Nephrology Unit at Chris Hani Baragwanath Academic Hospital

  2015cites this paper
• Hematological Changes in Patients of Chronic Renal Disease and Their Response to Treatment with Erythropoietin

  2015cites this paper
• Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period.

  2014cites this paper
• PEGINESATIDE- A NOVEL ERYTHROPOIETIN MIMETIC AGENT FOR THE TREATMENT OF ANAEMIA IN CHRONIC RENAL FAILURE PATIENTS

  2013cites this paper
• An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic

  2013cites this paper
• Anemia management: development of a rapidaccess anemia and intravenous iron service

  2013cites this paper
• Utilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings

  2012cites this paper
• Trends in the utilization of erythropoiesis-stimulating agents among Medicare beneficiaries with kidney disease

  2011cites this paper
• CE: Continuing Education Article: MANAGEMENT OF ANAEMIA IN CHRONIC KIDNEY DISEASE.

  2010cites this paper
• Assessment of control and performance of biomedical systems

  2010cites this paper
• Key insights into present and future treatments of anaemia in CKD patients

  2009cites this paper
• Overview of emerging pharmacotherapy in chronic heart failure

  2009cites this paper
• Future perspectives on treatment with erythropoiesis-stimulating agents in high-risk patients

  2009influential citation
• Key insights into present and future treatments of anaemia in CKD patients

  2009cites this paper
• Osteopathic Medicine and Primary Care looks forward to 2009

  2009cites this paper
• Overviewofemerging pharmacotherapyinchronic heartfailure

  2009cites this paper